Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 5 art units • 10 examiners • 0 of 12 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Ipsen Biopharm Limited is currently managing 12 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 12 pending office actions are distributed among 10 distinct examiners and 5 distinct art units. This indicates that while the company's pharmaceutical innovations are concentrated in 5 art units, they are being reviewed by a relatively diverse group of 10 examiners. The 5 distinct art units involved suggest that the company's biotechnology and pharmaceutical applications fall into several distinct technical categories within the USPTO.
SWIFT, CANDICE LEE is the busiest examiner for this portfolio, with 2 pending office actions. This count of 2 is a low concentration compared to the 12 total pending office actions, as most matters are handled by different examiners. The 10 distinct examiners assigned to the 12 pending office actions suggest that the company's legal team interacts with multiple individuals at the USPTO. Practitioners should be prepared for the varied examination styles of the 10 distinct examiners who oversee the pending applications. Maintaining consistency across the 5 distinct art units is a key consideration for this pharmaceutical portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 6 (50%) |
| Multi-statute (no §101) | 6 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWIFT, CANDICE LEE | 2 | 56.6% | +37.2% |
| DAVIS, RUTH A | 2 | 60.9% | +31.0% |
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| GANGLE, BRIAN J | 1 | 76.8% | +14.6% |
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
| GRASER, JENNIFER E | 1 | 76.8% | +23.2% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.8% | +41.2% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.2% | +38.9% |
| CLARKE, TRENT R | 1 | 42.2% | +24.7% |
| RAGHU, GANAPATHIRAM | 1 | 73.7% | +26.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17759674 | TREATMENT OF SKIN CONDITIONS | DAVIS, RUTH A | 40d |
| 19309183 | CHIMERIC NEUROTOXINS | DUFFY, PATRICIA ANN | — |
| 18914188 | TREATMENT OF AUTONOMIC DISORDERS WITH BOTULINUM TOXIN | JACKSON-TONGUE, LAKIA J | — |
| 18711047 | TREATMENT OF VISCERAL PAIN | GRASER, JENNIFER E | — |
| 18003570 | CONTROLLING OPERATION OF A BIOREACTOR VESSEL | CLARKE, TRENT R | — |
| 18003489 | TREATMENT OF POST-OPERATIVE SURGICAL PAIN | RAGHU, GANAPATHIRAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18096899 | TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES | DAVIS, RUTH A | 34d |
| 17759674 | TREATMENT OF SKIN CONDITIONS | DAVIS, RUTH A | 40d |
| 19309183 | CHIMERIC NEUROTOXINS | DUFFY, PATRICIA ANN | — |
| 19189864 | LIQUID NEUROTOXIN FORMULATION STABILIZED WITH TRYPTOPHAN OR TYROSINE | GANGLE, BRIAN J | — |
| 18914188 | TREATMENT OF AUTONOMIC DISORDERS WITH BOTULINUM TOXIN | JACKSON-TONGUE, LAKIA J | — |
| 18711047 | TREATMENT OF VISCERAL PAIN | GRASER, JENNIFER E | — |
| 18711074 | TREATMENT OF PAIN | OGUNBIYI, OLUWATOSIN A | — |
| 18690378 | Modified Bont/A for Use in the Treatment of Cervical Dystonia | SWIFT, CANDICE LEE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 5 |
| 1657 | 2 |
| 1651 | 2 |
| 1699 | 2 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19309183 | CHIMERIC NEUROTOXINS | DUFFY, PATRICIA ANN | 1645 | §102§103Other | Non-Final OA | — | Pending | Aug 25, 2025 |
| 19189864 | LIQUID NEUROTOXIN FORMULATION STABILIZED WITH TRYPTOPHAN OR TYROSINE | GANGLE, BRIAN J | 1645 | §112DP | Non-Final OA | — | Pending | Apr 25, 2025 |
| 18914188 | TREATMENT OF AUTONOMIC DISORDERS WITH BOTULINUM TOXIN | JACKSON-TONGUE, LAKIA J | 1645 | §102§103§112 | Non-Final OA | — | Pending | Oct 13, 2024 |
| 18711047 | TREATMENT OF VISCERAL PAIN | GRASER, JENNIFER E | 1645 | §103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18711074 | TREATMENT OF PAIN | OGUNBIYI, OLUWATOSIN A | 1645 | §102§103DP | Non-Final OA | — | Pending | May 16, 2024 |
| 18690378 | Modified Bont/A for Use in the Treatment of Cervical Dystonia | SWIFT, CANDICE LEE | 1657 | §103§112DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18690479 | Modified Bont/A for Use in the Treatment of a Disorder Affecting an Eyelid Muscle of a Subject | SWIFT, CANDICE LEE | 1657 | §103§112DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18552457 | CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN & INFLAMMATORY DISORDERS | PAGUIO FRISING, MICHELLE F | 1651 | §102§103DP | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18096899 | TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES | DAVIS, RUTH A | 1699 | §112DPOther | Final Rejection | 34d | Pending | Jan 13, 2023 |
| 18003570 | CONTROLLING OPERATION OF A BIOREACTOR VESSEL | CLARKE, TRENT R | 1651 | §102§103§112 | Non-Final OA | — | Pending | Dec 28, 2022 |
| 18003489 | TREATMENT OF POST-OPERATIVE SURGICAL PAIN | RAGHU, GANAPATHIRAM | 1652 | §102§103§112 | Final Rejection | — | Pending | Dec 27, 2022 |
| 17759674 | TREATMENT OF SKIN CONDITIONS | DAVIS, RUTH A | 1699 | §102§103§112Other | Non-Final OA | 40d | Pending | Jul 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIpsen Biopharm Limited has 12 pending office actions as of October 2026, spread across 5 art units and 10 examiners.
Candice Lee Swift has the most, with 2 of Ipsen Biopharm Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
